NOV 18, 2020 6:30 AM PST

Nerve Damage as a Prognostic Marker for Rare Autoimmune Disease

WRITTEN BY: Tara Fernandez

Researchers have identified a new prognostic biomarker for Guillain-Barré syndrome (GBS), a rare autoimmune disorder that attacks the nerves and can eventually paralyze the entire body. The biomarker, neurofilament light chain, or NfL, signals the presence of axonal damage. As published in the Journal of Neurology, Neurosurgery, and Psychiatry, high circulating levels of NfL in GBS patients were found to be associated with more severe disabilities.

These findings significantly impact the clinical strategies for managing GBS and increase neurologists' understanding of the physiological processes underlying this devastating disease.

"First, they confirm that residual long-term disability in GBS is clearly associated to the degree of axonal damage that happens at the onset of the disease," said Luis Querol, senior author of the study.

"They also suggest that serum NfL could be used to stratify patients at admission, and in the future, select patients who may be candidates for more aggressive therapies or those who may have good prognosis independently of the apparent severity they have at onset," said Querol.

The root causes of GBS continue to mystify scientists, although a large proportion of patients report having a severe respiratory or gastrointestinal infection in the leadup to the disease. Among the early signs of GBS are a prickling sensation in the fingers, limb weakness, and double vision.

Measuring the degeneration of axons, or nerve fibers, can determine a GBS patient’s outcomes and shape clinical interventions moving forward, said Bart Jacobs from the Erasmus Medical Center in Rotterdam. 

In an editorial on the study, Jacobs writes: "Axonal injury may occur in AMAN as well as acute inflammatory demyelinating polyneuropathy and in severe cases may result in irreversible degeneration. Treatment with immunoglobulins or plasma-exchange aims to prevent further axonal injury, but clinicians currently have no methods to monitor the response directly."

 

 

Sources: MedPage Today, Journal of Neurology, Neurosurgery & Psychiatry.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
MAY 14, 2021
Microbiology
An Imaging Tool for Seeing Bacterial Infections in the Body
MAY 14, 2021
An Imaging Tool for Seeing Bacterial Infections in the Body
Researchers have created an imaging agent that will allow scientists and clinicians to visualize a bacterial infection c ...
JUN 15, 2021
Cardiology
A Common Thread Among 20% of Sudden Cardiac Deaths
JUN 15, 2021
A Common Thread Among 20% of Sudden Cardiac Deaths
It's estimated that 450,000 Americans die from sudden heart conditions, and in about one in ten cases, the cause is unex ...
JUN 29, 2021
Immunology
Speed Up qPCR Sample Preparation for SARS-CoV-2 Detection
JUN 29, 2021
Speed Up qPCR Sample Preparation for SARS-CoV-2 Detection
Amid the widespread outbreak of the COVID-19 caused by SARS-CoV-2, the development of test methods that can efficiently ...
AUG 10, 2021
Clinical & Molecular DX
New CRISPR Device Diagnoses COVID in an Hour, Detects Variants
AUG 10, 2021
New CRISPR Device Diagnoses COVID in an Hour, Detects Variants
A team of engineers from MIT and Harvard University has developed a COVID diagnostic device with a tiny footprint but hu ...
AUG 31, 2021
Clinical & Molecular DX
Five Questions to Help You Select the Best Cellular Stain
AUG 31, 2021
Five Questions to Help You Select the Best Cellular Stain
Cellular stains are organic fluorescent dyes or fluorescent conjugates designed to localize to a specific organelle or c ...
SEP 09, 2021
Clinical & Molecular DX
A Drug Test for Synthetic Cannabis Use
SEP 09, 2021
A Drug Test for Synthetic Cannabis Use
Designer drugs are synthetic analogs of prohibited substances such as cocaine and LSD made in clandestine laboratories a ...
Loading Comments...